ProfileGDS5678 / 1424731_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 63% 63% 57% 63% 63% 62% 63% 63% 64% 63% 63% 67% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6944261
GSM967853U87-EV human glioblastoma xenograft - Control 23.7883563
GSM967854U87-EV human glioblastoma xenograft - Control 33.7904663
GSM967855U87-EV human glioblastoma xenograft - Control 43.3854557
GSM967856U87-EV human glioblastoma xenograft - Control 53.7303163
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8436663
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7937962
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7647663
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7883863
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8632764
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7721363
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7664963
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.03967
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8343964